Brian Abbott, MD
Medical Director of HematologyBig Sky Oncology
Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow transplants (BMT), myelodysplastic syndrome (MDS), and aplastic anemia. Dr. Abbott also treats significant numbers of lung, colon, and breast cancer patients. He has interest in venture capital and hedge fund due diligence, and investment analysis in early stage pharmaceutical companies. He has experience in consulting with venture capital firms regarding biotechnology start-up investment opportunities. He has a special interest in consulting with pharmaceutical companies regarding acquisitions and in design of clinical trials, and providing the insight of a physician who has worked in academic and community oncology practice environments. (This is me - Update Profile)
| 2007 - present | Medical Director of Hematology Big Sky Oncology |
|---|---|
| 2007 - present | Medical Director, Hematology Division Sletten Cancer Institute |
| 2005 - 2006 | Assistant Professor of Medicine University of Colorado Health Sciences Center |
GLG Study Groups with Brian Abbott, MD(?)
| Study Group Name | Members |
|---|---|
| Multiple Myeloma Physicians | 189 |
| Physicians who Treat CML (US) | 34 |
| Oncologists who Treat Hematologic Malignancies (US) | 881 |
| Hematologists and Oncologists in Private Practice (US) | 442 |
GLG NewsSM Analyses by Brian Abbott, MD(?)
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
There is no reason to believe Dacogen is inferior to Vidaza. In some studies, Dacogen seems to produce a deeper quality of response, and may also prove more beneficial in AML.
GLG InstituteSM Seminars with Brian Abbott, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Brian Abbott, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

